New T2D Guidelines; More Cushing's Relacorilant Data; Drug Shortages Rage On

The American College of Physicians released a new guideline for the pharmacological treatment of type 2 diabetes in adults, strongly recommending the addition of an SGLT2 inhibitor or GLP-1 receptor agonist, but not a DPP-4 inhibitor to metformin and lifestyle interventions to reduce all-cause mortality risk for those with inadequate glucose control. (Annals of Internal Medicine)

In related news, the American Diabetes Association released its abridged Standards of Care in Diabetes for primary care professionals. (Clinical Diabetes)

People with Cushing's syndrome on investigational relacorilant -- a selective cortisol modulator -- had rapid and sustained improvements in both systolic and diastolic blood pressure over 22 weeks, said Corcept Therapeutics. Responders who entered a withdrawal phase continued to have blood pressure improvements in the two-part phase III GRACE trial.

Senators are demanding answers from Novo Nordisk on why a popular long-acting insulin (Levemir) is being discontinued. (USA Today)

Almost all doses of the injectable tirzepatide (Mounjaro, Zepbound) for type 2 diabetes and obesity will be in short supply through the second quarter of this year, the FDA website showed. (Reuters)

And how should the supply of diabetes and obesity drugs be allocated? Experts weighed in. (New England Journal of Medicine)

Meanwhile, the continued shortage of the growth hormone somatropin (Norditropin) since fall 2022 is still affecting patients with hormone deficiencies like Prader-Willi syndrome. (NPR)

Under a new rule from the Environmental Protection Agency, polluters will have to pay to clean up perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) -- two so-called forever chemicals linked to serious health risks -- shifting responsibility from taxpayers. (New York Times)

"All of a sudden they'd quit smoking," said family nurse practitioner Luba Yammine, PhD, MSN, about prescribing GLP-1 receptor agonists to treat patients with type 2 diabetes, in a JAMA perspective.

People with type 1 diabetes following a low-fat vegan diet significantly reduced their average total daily dose of insulin over 12 weeks. On the other hand, those on a portion-controlled diet had no change in insulin needs. (Clinical Diabetes)

Racial discrimination in adolescence may predispose Black people to metabolic syndrome in adulthood, a longitudinal cohort study suggested. (JAMA Network Open)

Can the diabetes mainstay metformin slow down aging? Researchers are looking to find out. (NPR)

Real-world data showed a significantly lower incidence of hip fracture and non-vertebral fracture with abaloparatide (Tymlos) among women ages 50 and older with osteoporosis compared with teriparatide (Forteo), said Radius Pharmaceuticals.

Correction: A previous version of this roundup incorrectly stated that the American College of Physicians' guidelines recommended adding a DPP-4 inhibitor to metformin and lifestyle interventions to reduce all-cause mortality risk for those with type 2 diabetes and inadequate glucose control.

Comment